Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
Pharmaceutical Technology on MSN
JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement
AbbVie's deal with RemeGen is the first to be announced during the 2026 J.P Morgan Healthcare Conference, with more deals ...
First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of ...
3d
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Summit Therapeutics Inc. ( SMMT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM EST ...
RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancersNORTH CHICAGO, Ill.
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...
Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...
The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback